Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

Open-label, non-randomised, exploratory, phase II, multi-centre clinical trial. 43 unresectable stage III (IIIA-N2, IIIB, IIIC) KRAS p.G12C non-small cell lung cancer patients will be enrolled in this trial to evaluate the efficacy of induction treatment of AMG510 (Sotorasib) plus AMG510 (Sotorasib) treatment post-induction as measured by Progression Free Survival at 12 months.

Trial Details

NCT ID

NCT05398094

Phase

PHASE2

Sponsor

Fundación GECP

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

Sotorasib

Locations (sample)

Alicante, Alicante, Spain|38.34517,-0.48149
Badalona, Barcelona, Spain|41.45004,2.24741
Barcelona, Barcelona, Spain|41.38879,2.15899
Barcelona, Barcelona, Spain|41.38879,2.15899
Barcelona, Barcelona, Spain|41.38879,2.15899

Key Eligibility Criteria

1\. Male or female, aged ≤ 80 years old
2\. ECOG performance status of 0-1
3\. Histologically or cytologically confirmed, unresectable Stage III (IIIA-N2, IIIB and IIIC) NSCLC according to 8th version of the International …
4\. Patients who have documentation of KRAS p.G12C prior to enrollment. This determination can be done either by solid or liquid biopsy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →